NIH R01 · 2025
Understanding B-Lactam Resistance in Acinetobacter baumannii
The Centers for Disease Control and Prevention (CDC) designated Carbapenem-Resistant Acinetobacter baumannii (CRAb) an “urgent threat pathogen” for which novel therapies are desperately needed. The current COVID-19 pandemic has only accelerated the emergence of CRAb in medical intensive care units and hospitals, creating a parallel health care crisis in the US. The combination of β-lactamase production and cell penetration challenge every drug class used to treat CRAb. By applying novel chemistry to design more potent “cross-class” boronic acid transition state inhibitors (BATSIs) that are effective β-lactamase inactivators, and developing a deeper understanding of the genetic diversity of…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.